Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The institution currently has 1 pending office action. This activity is distributed across 1 distinct examiner and 1 distinct art unit. These numbers indicate a very specific and limited prosecution phase for the institution's current filings. The data does not show a broad range of active cases across different technical divisions. This focus suggests that the institution is advancing a particular research outcome through the patent office.
The busiest examiner for the portfolio is BAUSCH, SARAE L, who is handling 1 pending office action. This examiner is responsible for 1 busiest examiner pending case, which is the only pending action for the entire portfolio. This indicates that the institution's current interaction with the patent office is concentrated on this 1 individual. The involvement of 1 distinct art unit means that the technical evaluation is being conducted by 1 specialized unit. This concentration simplifies the management of the prosecution but also places the institution's immediate success in the hands of 1 examiner. The singular nature of the 1 distinct examiner allows for a very focused legal response and consistent technical arguments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.6% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374074 | Biomarkers Predictive Of Atopic Dermatitis That Facilitate Prevention And/Or Treatment of the Onset Atopic Dermatitis | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374074 | Biomarkers Predictive Of Atopic Dermatitis That Facilitate Prevention And/Or Treatment of the Onset Atopic Dermatitis | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18374074 | Biomarkers Predictive Of Atopic Dermatitis That Facilitate Prevention And/Or Treatment of the Onset Atopic Dermatitis | BAUSCH, SARAE L | 1699 | §101§102§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarae L Bausch has the most, with 1 of UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.